Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK) has granted inducement equity awards to four new employees, including stock options for 57,429 shares and restricted stock units for 43,071 shares. The stock options, priced at $28.15 per share, will vest 25% after one year and the remaining 75% in quarterly installments. The restricted stock units will vest in four equal annual installments. These grants, made under the company's 2022 Inducement Equity Plan, are designed to attract new talent to the late-stage biopharmaceutical company, which focuses on treatments for spinal muscular atrophy and cardiometabolic disorders.
Scholar Rock (NASDAQ: SRRK) ha concesso premi azionari di indennità a quattro nuovi dipendenti, inclusi opzioni su azioni per 57.429 azioni e unità di azioni vincolate per 43.071 azioni. Le opzioni su azioni, prezzate a $28,15 per azione, matureranno il 25% dopo un anno e il restante 75% in rate trimestrali. Le unità di azioni vincolate matureranno in quattro rate annuali uguali. Questi premi, concessi nell'ambito del Piano di Indennità Azionaria 2022 della società, sono progettati per attrarre nuovi talenti nella società biofarmaceutica in fase avanzata, che si concentra su trattamenti per l'atrofia muscolare spinale e i disturbi cardiometabolici.
Scholar Rock (NASDAQ: SRRK) ha otorgado premios en acciones por inducimiento a cuatro nuevos empleados, incluidos opciones sobre acciones para 57,429 acciones y unidades de acciones restringidas para 43,071 acciones. Las opciones sobre acciones, valoradas en $28.15 por acción, se consolidarán en un 25% después de un año y el 75% restante en cuotas trimestrales. Las unidades de acciones restringidas se consolidarán en cuatro cuotas anuales iguales. Estas concesiones, realizadas bajo el Plan de Inducimiento de Capital de 2022 de la empresa, están diseñadas para atraer nuevo talento a la empresa biofarmacéutica en etapa avanzada, que se centra en tratamientos para la atrofia muscular espinal y trastornos cardiometabólicos.
Scholar Rock (NASDAQ: SRRK)은 4명의 신규 직원에게 유인 주식 보상을 부여했으며, 여기에는 57,429주에 대한 스톡 옵션과 43,071주에 대한 제한주식단위가 포함됩니다. 스톡 옵션은 주당 $28.15의 가격으로 제공되며, 1년 후 25%가 베스팅되고 나머지 75%는 분기마다 할당됩니다. 제한주식단위는 4개의 동일한 연간 분할로 베스팅됩니다. 2022년 유인 주식 계획에 따라 부여된 이 보상은 척수근육위축 및 심장대사 장애에 대한 치료에 집중하는 후기 단계 바이오 제약 회사에 새로운 인재를 유치하기 위해 설계되었습니다.
Scholar Rock (NASDAQ: SRRK) a octroyé des récompenses d'équité d'incitation à quatre nouveaux employés, y compris des options d'achat d'actions pour 57 429 actions et des unités d'actions restreintes pour 43 071 actions. Les options d'achat d'actions, évaluées à 28,15 $ par action, se débloqueront à 25 % après un an et les 75 % restants par trimestres. Les unités d'actions restreintes se débloqueront en quatre versements annuels égaux. Ces attributions, effectuées dans le cadre du Plan d'Équité d'Incitation 2022 de l'entreprise, visent à attirer de nouveaux talents dans cette entreprise biopharmaceutique d'étape avancée, qui se concentre sur des traitements pour l'atrophie musculaire spinale et les troubles cardiométaboliques.
Scholar Rock (NASDAQ: SRRK) hat vier neuen Mitarbeitern Anreizzuwendungen in Form von Eigenkapital angeboten, darunter Aktienoptionen für 57.429 Aktien und beschränkte Aktieneinheiten für 43.071 Aktien. Die Aktienoptionen, die mit 28,15 $ pro Aktie bewertet sind, werden zu 25% nach einem Jahr und die verbleibenden 75% in vierteljährlichen Raten fällig. Die beschränkten Aktieneinheiten werden in vier gleichen jährlichen Raten fällig. Diese Vergaben, die im Rahmen des Unternehmensplans für Anreizzuwendungen von 2022 gemacht wurden, sollen neue Talente für das spätstadiale Biopharmaunternehmen gewinnen, das sich auf Behandlungen für spinale Muskelatrophie und kardiometabolische Störungen konzentriert.
- Successful attraction of new talent through equity incentives
- Stock options priced at market value ($28.15), aligning with shareholder interests
- Potential dilution of existing shareholders through new equity issuance of 100,500 shares
The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.
The Plan, initially adopted by the Company’s board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rule 5635(c)(4).
The inducement stock options have an exercise price of
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241115276975/en/
Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Media
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-5995
Source: Scholar Rock
FAQ
What inducement equity awards did Scholar Rock (SRRK) grant to new employees?
What is the exercise price of Scholar Rock's (SRRK) new inducement stock options?
How do the vesting terms work for Scholar Rock's (SRRK) inducement awards?
